Zydus Cadila Reels After Double FDA Warning
This article was originally published in PharmAsia News
Shares of Cadila Healthcare were pounded on Indian bourses on New Year's Eve after the US FDA issued warning letters against two of the firm's Indian sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were already underway.
You may also be interested in...
Cadila Healthcare’s scion Dr Sharvil Patel takes charge as managing director as the frontline Indian company transitions to its next phase of growth and aspires for a more innovation-driven avatar.
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.